AAAAAA
Results:
1-16
|
Results: 16
Authors:
Krebs, MO
Gut-Fayand, A
Amado, I
Daban, C
Bourdel, MC
Poirier, MF
Berthoz, A
Citation: Mo. Krebs et al., Impairment of predictive saccades in schizophrenia, NEUROREPORT, 12(3), 2001, pp. 465-469
Authors:
Laqueille, X
Poirier, MF
Jalfre, V
Bourdel, MC
Willard, D
Olie, JP
Citation: X. Laqueille et al., Factors predicting the response to buprenorphine in substitutive therapy of heroin addicts - Results of a multicenter study of 73 patients, PRESSE MED, 30(32), 2001, pp. 1581-1585
Authors:
Gut-Fayand, A
Dervaux, A
Olie, JP
Loo, H
Poirier, MF
Krebs, MO
Citation: A. Gut-fayand et al., Substance abuse and suicidality in schizophrenia: a common risk factor linked to impulsivity, PSYCHIAT R, 102(1), 2001, pp. 65-72
Authors:
Leroy, S
Griffon, N
Bourdel, MC
Olie, JP
Poirier, MF
Krebs, MO
Citation: S. Leroy et al., Schizophrenia and the cannabinoid receptor type 1 (CB1): Association studyusing a single-base polymorphism in coding exon 1, AM J MED G, 105(8), 2001, pp. 749-752
Authors:
Krebs, MO
Guillin, O
Bourdel, MC
Schwartz, JC
Olie, JP
Poirier, MF
Sokoloff, P
Citation: Mo. Krebs et al., Brain Derived Neurotrophic Factor (BDNF) gene variants association with age at onset and therapeutic response in schizophrenia, MOL PSYCHI, 5(5), 2000, pp. 558-562
Authors:
Ito, C
Morisset, S
Krebs, MO
Olie, JP
Loo, H
Poirier, MF
Lannfelt, L
Schwartz, JC
Arrang, JM
Citation: C. Ito et al., Histamine H-2 receptor gene variants: lack of association with schizophrenia, MOL PSYCHI, 5(2), 2000, pp. 159-164
Authors:
Duaux, E
Krebs, MO
Loo, H
Poirier, MF
Citation: E. Duaux et al., Genetic vulnerability to drug abuse, EUR PSYCHIA, 15(2), 2000, pp. 109-114
Authors:
Galinowski, A
Castelnau, C
Spreux-Varoquaux, O
Bourdel, MC
Olie, JP
Loo, H
Poirier, MF
Citation: A. Galinowski et al., Evolution of Plasma Homovanillic Acid (HVA) levels during treatment in schizo-affective disorder, PROG NEUR-P, 24(8), 2000, pp. 1319-1328
Authors:
Poirier, MF
Citation: Mf. Poirier, Drug treatment for resistant depression - Author's reply, BR J PSYCHI, 176, 2000, pp. 398-398
Authors:
Millet, B
Touitou, Y
Poirier, MF
Bourdel, MC
Amado, I
Hantouche, EG
Bogdan, A
Olie, JP
Citation: B. Millet et al., Obsessive-compulsive disorder: evaluation of clinical and biological circadian parameters during fluoxetine treatment, PSYCHOPHAR, 146(3), 1999, pp. 268-274
Authors:
Kazes, M
Berthet, L
Danion, JM
Amado, I
Willard, D
Robert, P
Poirier, MF
Citation: M. Kazes et al., Impairment of consciously controlled use of memory in schizophrenia, NEUROPSYCHL, 13(1), 1999, pp. 54-61
Authors:
Poirier, MF
Boyer, P
Citation: Mf. Poirier et P. Boyer, Venlafaxine and paroxetine in treatment-resistant depression - Double-blind, randomised comparison, BR J PSYCHI, 175, 1999, pp. 12-16
Authors:
Poirier, MF
Boyer, P
Citation: Mf. Poirier et P. Boyer, Venlafaxine and paroxetine in treatment-resistant depression - Double-blind, randomised comparison (vol 175, pg 12, 1999), BR J PSYCHI, 175, 1999, pp. 394-394
Authors:
Poirier, MF
Boyer, P
Citation: Mf. Poirier et P. Boyer, Venlafaxine and paroxetine in treatment-resistant depression - Reply, BR J PSYCHI, 175, 1999, pp. 591-591
Authors:
Attar-Levy, D
Martinot, JL
Blin, J
Dao-Castellana, MH
Crouzel, C
Mazoyer, B
Poirier, MF
Bourdel, MC
Aymard, N
Syrota, A
Feline, A
Citation: D. Attar-levy et al., The cortical serotonin(2) receptors studied with positron-emission tomography and [F-18]-setoperone during depressive illness and antidepressant treatment with clomipramine, BIOL PSYCHI, 45(2), 1999, pp. 180-186
Authors:
Poirier, MF
Citation: Mf. Poirier, Trends in clinical psychiatric research, PRESSE MED, 27(40), 1998, pp. 2185-2189
Risultati:
1-16
|